Compare LCII & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCII | PHVS |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | 1994 | 2020 |
| Metric | LCII | PHVS |
|---|---|---|
| Price | $105.88 | $34.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $130.86 | $41.82 |
| AVG Volume (30 Days) | ★ 426.5K | 371.0K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ 35.18 | N/A |
| EPS | ★ 2.53 | N/A |
| Revenue | ★ $4,122,017,000.00 | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.25 | N/A |
| P/E Ratio | $39.72 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $84.33 | $17.24 |
| 52 Week High | $159.66 | $35.33 |
| Indicator | LCII | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 64.71 |
| Support Level | $103.85 | $24.73 |
| Resistance Level | $113.58 | N/A |
| Average True Range (ATR) | 3.80 | 1.63 |
| MACD | 2.09 | 0.20 |
| Stochastic Oscillator | 96.03 | 70.36 |
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries, including buses and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments: the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.